Access the full text.
Sign up today, get DeepDyve free for 14 days.
Doreen Agnese, Kimberly Allison, Sarah Blair, Harold Burstein, Anthony Elias, Sharon Giordano, Matthew Goetz, Lori Goldstein (2019)
NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY
Weihua Li, T. Qiu, Lei Guo, Y. Ling, Yibo Gao, J. Ying, Jie He (2018)
Primary and acquired EGFR T790M-mutant NSCLC patients identified by routine mutation testing show different characteristics but may both respond to osimertinib treatment.Cancer letters, 423
Metastatic nonsmall cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. European Society of Medical Oncology
(National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: non-small cell lung cancer. Version 3.2020. National Comprehensive Cancer Network. 2020. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed August 3 2020)
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: non-small cell lung cancer. Version 3.2020. National Comprehensive Cancer Network. 2020. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed August 3 2020National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: non-small cell lung cancer. Version 3.2020. National Comprehensive Cancer Network. 2020. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed August 3 2020, National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: non-small cell lung cancer. Version 3.2020. National Comprehensive Cancer Network. 2020. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed August 3 2020
(Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. European Society of Medical Oncology. 2019. https://www.esmo.org/content/download/227453/3874538/1. Accessed August 3 2020)
Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. European Society of Medical Oncology. 2019. https://www.esmo.org/content/download/227453/3874538/1. Accessed August 3 2020Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. European Society of Medical Oncology. 2019. https://www.esmo.org/content/download/227453/3874538/1. Accessed August 3 2020, Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. European Society of Medical Oncology. 2019. https://www.esmo.org/content/download/227453/3874538/1. Accessed August 3 2020
C. Miaskowski, Kathryn Lee (1999)
Pain, fatigue, and sleep disturbances in oncology outpatients receiving radiation therapy for bone metastasis: a pilot study.Journal of pain and symptom management, 17 5
F. Lagerwaard, PeterC Levendag, PeterJ.C.M Nowak, WilhelminaM.H Eijkenboom, PatrickE.J Hanssens, PaulI.M Schmitz (1999)
Identification of prognostic factors in patients with brain metastases: a review of 1292 patients.International journal of radiation oncology, biology, physics, 43 4
(2019)
IMpower150: analysis of efficacy in patients (pts) with liver metastases (mets)J Clin Oncol, 37
Y. Lou, B. Dholaria, A. Soyano, D. Hodge, J. Cochuyt, R. Manochakian, S. Ko, Mathew Thomas, Margaret Johnson, Neal Patel, RobertI Miller, A. Adjei, S. Ailawadhi (2018)
Survival trends among non‐small‐cell lung cancer patients over a decade: impact of initial therapy at academic centersCancer Medicine, 7
(2019)
Metastatic nonsmall cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
S. Goldberg, S. Gettinger, A. Mahajan, A. Chiang, R. Herbst, M. Sznol, A. Tsiouris, J. Cohen, A. Vortmeyer, Lucia Jilaveanu, James Yu, U. Hegde, Stephanie Speaker, Matthew Madura, A. Ralabate, A. Rivera, E. Rowen, H. Gerrish, Xiaopan Yao, V. Chiang, H. Kluger (2016)
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.The Lancet. Oncology, 17 7
Jiaxin Zhu, Tian-tian Zhang, Jiahao Li, Junming Lin, W. Liang, Wenjie Huang, Ning Wan, Jie Jiang (2019)
Association Between Tumor Mutation Burden (TMB) and Outcomes of Cancer Patients Treated With PD-1/PD-L1 Inhibitions: A Meta-AnalysisFrontiers in Pharmacology, 10
A. Naqash, C. Stroud, M. Butt, G. Dy, A. Hegde, M. Muzaffar, Li Yang, M. Hafiz, C. Cherry, P. Walker (2017)
Co-relation of overall survival with peripheral blood-based inflammatory biomarkers in advanced stage non-small cell lung cancer treated with anti-programmed cell death-1 therapy: results from a single institutional databaseActa Oncologica, 57
(2021)
key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
IMpow - er 150 final analysis : efficacy of atezolizumab and chemotherapy ± bevacizumab in first - line metastatic non - squamous non - small cell lung cancer across key subgroups Cancer Res
D. Pfister, K. Ang, D. Brizel (2012)
National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology
L. Landi, F. D’Incà, A. Gelibter, R. Chiari, F. Grossi, A. Delmonte, A. Passaro, D. Signorelli, F. Gelsomino, D. Galetta, D. Giannarelli, H. Parra, G. Minuti, M. Tiseo, M. Migliorino, F. Cognetti, L. Toschi, P. Bidoli, F. Piantedosi, L. Calabrò, F. Cappuzzo (2019)
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancerJournal for Immunotherapy of Cancer, 7
(2017)
zolizumab versus docetaxel in patients with previously treated non - small - cell lung cancer ( OAK ) : a phase 3 , open - label , multicentre randomised controlled trial
L. Fehrenbacher, A. Spira, M. Ballinger, M. Kowanetz, J. Vansteenkiste, J. Mazières, Keunchil Park, David Smith, A. Artal-Cortes, C. Lewanski, F. Braiteh, D. Waterkamp, P. He, W. Zou, Daniel Chen, J. Yi, A. Sandler, A. Rittmeyer (2016)
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trialThe Lancet, 387
Peter Harrison, S. Vyse, Paul Huang (2020)
Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancerSeminars in Cancer Biology, 61
H. Sugiura, Kenji Yamada, T. Sugiura, T. Hida, T. Mitsudomi (2008)
Predictors of Survival in Patients With Bone Metastasis of Lung CancerClinical Orthopaedics and Related Research, 466
(2020)
IMpower150 final analysis: efficacy of atezolizumab and chemotherapy ± bevacizumab in first-line metastatic non-squamous non-small cell lung cancer across key subgroups
D. Gandara, S. Paul, M. Kowanetz, E. Schleifman, W. Zou, Yan Li, A. Rittmeyer, L. Fehrenbacher, G. Otto, C. Malboeuf, Daniel Lieber, D. Lipson, J. Silterra, L. Amler, T. Riehl, C. Cummings, P. Hegde, A. Sandler, M. Ballinger, D. Fabrizio, T. Mok, D. Shames (2018)
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumabNature Medicine, 24
C. Langer, S. Gadgeel, H. Borghaei, V. Papadimitrakopoulou, A. Patnaik, S. Powell, R. Gentzler, R. Martins, J. Stevenson, S. Jalal, A. Panwalkar, J. Yang, M. Gubens, L. Sequist, M. Awad, J. Fiore, Y. Ge, H. Raftopoulos, L. Gandhi (2016)
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.The Lancet. Oncology, 17 11
M. Socinski, R. Jotte, F. Cappuzzo, F. Orlandi, D. Stroyakovskiy, N. Nogami, D. Rodríguez-Abreu, D. Moro-Sibilot, C. Thomas, F. Barlesi, G. Finley, C. Kelsch, Anthony Lee, S. Coleman, Y. Deng, Yijing Shen, M. Kowanetz, A. López-Chávez, A. Sandler, M. Reck (2018)
Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLCThe New England Journal of Medicine, 378
A. Rittmeyer, F. Barlesi, D. Waterkamp, Keunchil Park, F. Ciardiello, J. Pawel, S. Gadgeel, T. Hida, D. Kowalski, M. Dols, D. Cortinovis, J. Leach, J. Polikoff, C. Barrios, F. Kabbinavar, O. Frontera, F. Marinis, H. Turna, Jong-Seok Lee, M. Ballinger, M. Kowanetz, P. He, Daniel Chen, A. Sandler, D. Gandara (2017)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trialThe Lancet, 389
Yongfeng Wu, Jinming Xu, Chengli Du, Yihua Wu, D. Xia, W. Lv, Jian Hu (2019)
The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-AnalysisFrontiers in Oncology, 9
M. Reck, T. Mok, M. Nishio, R. Jotte, F. Cappuzzo, F. Orlandi, D. Stroyakovskiy, N. Nogami, D. Rodríguez-Abreu, D. Moro-Sibilot, C. Thomas, F. Barlesi, G. Finley, Anthony Lee, S. Coleman, Y. Deng, M. Kowanetz, G. Shankar, W. Lin, M. Socinski (2019)
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.The Lancet. Respiratory medicine, 7 5
M. Reck, R. Jotte, F. Cappuzzo, Tony Mok, Howard West, M. Nishio, V. Papadimitrakopoulou, F. Orlandi, D. Stroyakovskii, C. Thomas, N. Nogami, F. Barlesi, Anthony Lee, G. Shankar, Wei Yu, M. Ballinger, I. Bāra, Alan Sandler, M. Socinski (2020)
IMpower150: analysis of efficacy in patients (pts) with liver metastases (mets)Pneumologie, 74
T. Lu, Xiaodong Yang, Yiwei Huang, Mengnan Zhao, Ming Li, K. Ma, Jiacheng Yin, C. Zhan, Qun Wang (2019)
Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decadesCancer Management and Research, 11
F. Bray, J. Ferlay, I. Soerjomataram, R. Siegel, Lindsey Torre, A. Jemal (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesCA: A Cancer Journal for Clinicians, 68
Jong Kim, A. Kronbichler, M. Eisenhut, Sung Hong, H. Vliet, Jeonghyun Kang, J. Shin, G. Gamerith (2019)
Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-AnalysisCancers, 11
Hannah Blair (2018)
Atezolizumab: A Review in Previously Treated Advanced Non-Small Cell Lung CancerTargeted Oncology, 13
L. Gandhi, D. Rodríguez-Abreu, S. Gadgeel, E. Esteban, E. Felip, F. Angelis, M. Dómine, P. Clingan, M. Hochmair, S. Powell, S. Cheng, H. Bischoff, N. Peled, F. Grossi, R. Jennens, M. Reck, R. Hui, E. Garon, M. Boyer, B. Rubio-Viqueira, S. Novello, T. Kurata, J. Gray, J. Vida, Ziwen Wei, Jing Yang, H. Raftopoulos, C. Pietanza, M. Garassino (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung CancerThe New England Journal of Medicine, 378
Brandon Golding, Anita Luu, Robert Jones, A. Viloria‐Petit (2018)
The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC)Molecular Cancer, 17
MA Socinski (2020)
10.1158/1538-7445.AM2020-CT216Cancer Res, 80
M. Delgado-Rodríguez, M. Sillero-arenas (2017)
Systematic review and meta-analysis.Medicina intensiva, 42 7
Atezolizumab is a monoclonal antibody targeting the programmed death ligand 1 (PD-L1) that was approved in 2017 in the USA and Europe for the second-line treatment of advanced or metastatic non-small cell lung cancer (NSCLC). This review article describes the practical clinical issues associated with atezolizumab treatment in NSCLC using a combination of four illustrative cases and a narrative literature review. The first two cases highlight the importance of tumor mutational status when making treatment decisions. A 62-year-old man with epidermal growth factor receptor (EGFR)-mutated, PD-L1-positive, stage IV lung adenocarcinoma received treatment with second-line atezolizumab + bevacizumab, carboplatin, and paclitaxel (BCP) after first-line osimertinib. In the second case, a 63-year-old man with stage IVb lung adenocarcinoma with anaplastic lymphoma kinase (ALK) translocation received sixth-line treatment with atezolizumab + BCP. The two final cases both had extensive metastases. A 55-year-old woman with EGFR-mutated lung adenocarcinoma received second-line treatment with atezolizumab + BCP after development of multiple metastases, followed by atezolizumab + bevacizumab until last follow-up. A 42-year-old man with PD-L1-positive pulmonary adenocarcinoma (negative for EGFR mutations) developed liver and brain metastases after several lines of therapy. He underwent holocranial radiation and received atezolizumab + BCP, which resulted in a decrease in all measurable and evaluable tumoral lesions. These illustrative cases indicate that the type and number of mutations may influence treatment response to atezolizumab, and that atezolizumab may provide clinical benefit in patients with high disease burden.
Oncology and Therapy – Springer Journals
Published: Feb 13, 2021
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.